<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707651</url>
  </required_header>
  <id_info>
    <org_study_id>NASH</org_study_id>
    <nct_id>NCT04707651</nct_id>
  </id_info>
  <brief_title>Formula Diet Treatment for NASH Patients.</brief_title>
  <acronym>NASH</acronym>
  <official_title>Formula Diet Treatment for Weight Reduction in NASH Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Center of Diabetes and Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West German Center of Diabetes and Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic steatohepatitis (NASH) - also called fatty liver - is medically a serious&#xD;
      problem because the liver tissue becomes fatty and stiff, and inflammatory reactions occur.&#xD;
      This increases the risk of liver fibrosis (= scarring of the liver), liver cirrhosis (=&#xD;
      shrunken liver), a liver tumor or death. So far there is no recognized treatment option for&#xD;
      this disease. However, there is evidence that a lifestyle change based on a reduced&#xD;
      carbohydrate diet, more exercise and a significant weight loss that can improve NASH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outpatients with NASH will be included into this lifestyle intervention study. Patients will&#xD;
      get nutritional advices and a formula diet for 12 weeks. Clinical visits will take place at&#xD;
      baseline, after 4, 12 and after 52 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Lifestyle intervention including formula diet</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>degree of steatosis</measure>
    <time_frame>12 weeks</time_frame>
    <description>degree of steatosis in decibels per meter (dB/m) measured by Controlled Attenuation Parameter (CAP) estimation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>degree of steatosis</measure>
    <time_frame>52 weeks</time_frame>
    <description>degree of steatosis in decibels per meter (dB/m) measured by Controlled Attenuation Parameter (CAP) estimation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>degree of fibrosis</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <description>degree of fibrosis in meter per second (m/s) measured by Acoustic Radiation Force Impulse (ARFI) elastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fat mass</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <description>fatt mass in kilogram (kg) measured by Bioelectrical Impedance Analysis (BIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamate Pyruvate Transaminase (GPT)</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <description>Glutamate Pyruvate Transaminase in units/litre (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyltransferase (GGT)</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <description>Gamma-glutamyltransferase in units/litre (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <description>insulin in micro units per millilitre (µU/ml)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Steatohepatitis, Nonalcoholic</condition>
  <arm_group>
    <arm_group_label>Lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutrition advices and formula diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Formula diet</intervention_name>
    <description>Formula diet for 12 weeks</description>
    <arm_group_label>Lifestyle intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI&gt;25 kg/qm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of drug or alcohol abuse&#xD;
&#xD;
          -  acute or chronic diseases (except type 2 diabetes)&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West-German Centre of Diabetes and Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Martin, MD</last_name>
    <phone>+49(0)211-5660360</phone>
    <phone_ext>70</phone_ext>
    <email>stephan.martin@uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerstin Kempf, PhD</last_name>
    <phone>+49(0)211-5660360</phone>
    <phone_ext>16</phone_ext>
    <email>kerstin.kempf@wdgz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Düsseldorf Catholic Hospital Group</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40591</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin</last_name>
    </contact>
    <contact_backup>
      <last_name>Kempf</last_name>
    </contact_backup>
    <investigator>
      <last_name>Stephan Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Prof. Erhardt</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Erhardt, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Christian Laumann</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andreas Erhardt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Laumann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West German Center of Diabetes and Health</investigator_affiliation>
    <investigator_full_name>Stephan Martin</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>overweight</keyword>
  <keyword>fatty liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

